As artificial intelligence (AI) continues to make significant advances, the leaders of clinical trials should not underestimate its capabilities for improving patient recruitment, retention
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh